Finally, alterations in PI3K and MAPK pathways have been shown to cause resistance to HER2-based therapies [78,79], and phase III clinical trials are now underway to treat advanced HER2+ breast cancer harboring PIK3CA mutations using the PI3K p110α-specific inhibitor alpelisib (NCT04208178). The gene discussed is ERBB2; the disease is breast carcinoma.